uniQure N.V. Ordinary Shares (QURE)

FairStock Score: 41/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham style investor, I start with whether the business earns money and what protects it. uniQure does not. In fiscal 2025, the year ended 2025-12-31, it reported revenue of $16.1M and a net loss of $199.0M, or diluted EPS of -$3.46. In fiscal 2024, the year ended 2024-12-31, revenue was $27.1M with a net loss of $239.6M; fiscal 2023 was similar: $15.8M revenue and a $308.5M loss. The latest quarter, 2026-Q2, showed revenue of $5.8M and a net loss of $81.1M. Revenue growth of 11.00% pales beside profit growth of -114.90%. FairStock's trailing free cash flow is -$161.5M, a -12.0% FCF yield, so cash is being consumed, not produced. Debt-to-equity is 1.70, and FairStock's Altman Z-score of -0.09 suggests real financial distress risk. FairStock's return on equity is -157.61% and ROCE -15.72%, not signs of a wonderful business. FairStock's P/B of 4.56 at the 2026-10-13 close of $21.28 offers little asset-based support, and the negative P/E means earnings provide no valuation anchor. The FairStock score is 41/100, and the Piotroski F-score is 4/9. There may be optionality in HEMGENIX and AMT-130, but that is scientific and regulatory speculation, not a proven moat. The stock has traded between $8.73 and $71.50 in the past year, showing how binary sentiment can be. Graham would demand a margin of safety; Buffett would demand a durable franchise and predictable economics. Neither is evident in these figures.

In plain English: uniQure is a small biotechnology company that develops gene therapies for rare diseases, including hemophilia B and Huntington's disease. The business looks weak financially: it brings in very little revenue and loses much more money than it earns, with cash going out the door. At the 2026-10-13 close of $21.28, the shares look expensive compared with those losses, even though they are far below their 52-week high.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer